Adaptive Biotechnologies Corporation $ADPT Position Lowered by Cinctive Capital Management LP

Cinctive Capital Management LP trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 49.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 310,313 shares of the company’s stock after selling 305,431 shares during the period. Cinctive Capital Management LP owned 0.20% of Adaptive Biotechnologies worth $4,642,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sound Income Strategies LLC acquired a new stake in Adaptive Biotechnologies during the third quarter valued at approximately $30,000. Smartleaf Asset Management LLC grew its position in shares of Adaptive Biotechnologies by 593.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at approximately $133,000. Keybank National Association OH bought a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at approximately $155,000. Finally, Caprock Group LLC acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at approximately $163,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $13.17 on Monday. Adaptive Biotechnologies Corporation has a 12-month low of $6.68 and a 12-month high of $20.76. The firm has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. The business has a 50 day simple moving average of $16.55 and a 200 day simple moving average of $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue for the quarter was up 51.0% on a year-over-year basis. During the same period last year, the company earned ($0.23) earnings per share. Research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ADPT shares. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research note on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.25.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 141,583 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07. Following the sale, the chief operating officer owned 516,610 shares of the company’s stock, valued at $6,865,746.90. This trade represents a 21.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Chad M. Robins sold 470,167 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $6,192,099.39. Following the completion of the sale, the chief executive officer owned 2,301,113 shares in the company, valued at approximately $30,305,658.21. This represents a 16.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 2,350,698 shares of company stock valued at $34,449,277. Corporate insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.